Table 2 Cohort Characteristics at baseline between subgroups: stratified by sputum availability and follow-up status

From: CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial

Characteristics at Baseline

Sputum with FU N = 11

Sputum no FU N = 7*

No Sputum N = 16

Statistics

Sex

Female n (%)

5 (45%)

5 (71%)

9 (56%)

FT: p = 0.38

Age in years

Median (IQR)

26(23,32)

28 (21, 30)

16 (9, 28)

KW: χ2 = 4.5, p = 0.11

Age groups

>=20 n (%)

10 (91%)

5 (71%)

8 (50%)

FT: p = 0.03; Spu NFU - NoSpu: p = 0.17; Spu FU - NoSpu: p = 0.03; Spu FU - Spu NFU: p = 0.35

12-19 n (%)

1 (9.1%)

1 (14%)

1 (6.3%)

<=11 n (%)

0

1 (14%)

7 (44%)

Mutation

F508del homozygous n (%)

9 (82%)

5 (71%)

12 (75%)

FT: p = 0.7

Lung function

ppFEV1 Median (IQR)

69 (52, 76)

79 (69, 83)

94 (82, 99)

KW: χ2 = 6.5, p = 0.04; Spu NFU - NoSpu W: p = 0.18; Spu FU - NoSpu W: p = 0.02; Spu FU - Spu NFU W: p = 0.23

ppFVC Median (IQR)

84 (80, 96)

94 (91, 100)

100 (93, 115)

KW: χ2 = 4.2, p = 0.12

Sweat chloride

[mmol/l] Median (IQR)

85 (77, 95)

97.2 (88.5, 99.4)

82 (78, 93)

KW: χ2 = 4.8, p = 0.09

Bacterial culture results in sputum

Staphylococcus aureus pos. n (%)

7 (64%)

4 (57%)

NA

FT: p = 1

Pseudomonas aeruginosa pos. n (%)

7 (64%)

3 (43%)

NA

FT: p = 0.6

  1. FU follow-up, N number of participants, n(%) number and percentage of participants, IQR interquartile range, ppFEV1 percent predicted forced expiratory volume in 1 second, ppFVC percent predicted forced vital capacity. Statistical tests used: FT Fisher’s exact test, KW Kruskal-Wallis test, W Wilcoxon rank-sum test for post-hoc pairwise comparisons where applicable. Significant p-values are depicted in bold. NA = not applicable (no sputum sample available for microbiological assessment).
  2. * 1 patient (IMP8) provided a single sputum sample at Visit 9, but no baseline sample, and is not accounted for in this subgroup analysis.
Back to article page